Irritable bowel syndrome (IBS) is a complex functional gastrointestinal disorder that is exceedingly common in clinical practice. IBS with predominant constipation (IBS-C) is a subtype of IBS that accounts for more than a third of the IBS diagnosed.
Actavis and Ironwood Pharmaceuticals announced that top-line data demonstrate linaclotide (Linzess) met all primary and secondary endpoints, covering multiple abdominal...
Eluxadoline (Truberzi) is an orally administered, minimally absorbed agent that acts locally in the gastrointestinal tract as a mixed µ-opioid receptor agonist and δ-opioid receptor antagonist.
Almirall, S.A. and Ironwood Pharmaceuticals, Inc. announced that the European Commission has granted marketing authorization to Constella (linaclotide 290mcg) for...
Astellas Pharma and Ironwood Pharmaceuticals announced top-line results indicating that the Phase III clinical trial of Linzess (linaclotide) conducted in...
Ironwood Pharmaceuticals announced that the Phase III clinical trial of its 72 µg dose of Linzess/Constella (linaclotide) in adults with...
Ironwood Pharmaceuticals and Allergan announced positive topline data from a Phase IIIb clinical trial evaluating Linzess (linaclotide) 290 mcg on...
This guideline covers diagnosing and managing irritable bowel syndrome (IBS) in people aged 18 and over.
Constella is indicated for the symptomatic treatment of moderate to severe irritable bowel syndrome with constipation (IBS-C) in adults.